U.S. Markets closed
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • Dow 30

    34,347.03
    +152.97 (+0.45%)
     
  • Nasdaq

    11,226.36
    -58.96 (-0.52%)
     
  • Russell 2000

    1,869.19
    +5.67 (+0.30%)
     
  • Crude Oil

    76.28
    -1.66 (-2.13%)
     
  • Gold

    1,754.00
    +8.40 (+0.48%)
     
  • Silver

    21.43
    +0.06 (+0.29%)
     
  • EUR/USD

    1.0405
    -0.0008 (-0.0728%)
     
  • 10-Yr Bond

    3.6910
    -0.0150 (-0.40%)
     
  • Vix

    20.50
    +0.08 (+0.39%)
     
  • GBP/USD

    1.2091
    -0.0023 (-0.1935%)
     
  • USD/JPY

    139.1000
    +0.5100 (+0.3680%)
     
  • BTC-USD

    16,517.65
    +10.82 (+0.07%)
     
  • CMC Crypto 200

    386.97
    +4.32 (+1.13%)
     
  • FTSE 100

    7,486.67
    +20.07 (+0.27%)
     
  • Nikkei 225

    28,283.03
    -100.06 (-0.35%)
     

Amarin Still Suspends FY22 Guidance On Generic Challenges

  • Amarin Corporation plc (NASDAQ: AMRNcontinues suspending 2022 revenue guidance citing the ongoing global impact of COVID-19, the uncertainty resulting from the impact of generic IPE availability in the U.S., and challenges for most drugs seeking market access in Europe.

  • "In the second quarter of 2022, we made important progress on our long-term growth strategy. Our achievements give us confidence in the direction of and opportunities for Amarin during the remainder of 2022 and into 2023," said CEO Karim Mikhail.

  • Amarin reiterates that current cash, investments, and other assets are adequate to support continued operations, including European launch activities for at least the next twelve months.

  • The company reported Q2 sales of $94.4 million, a decrease of 39% driven by a decline in volume and net selling price due to an increase in generic competition in the U.S.

  • During Q2, there were three generic competitors in the U.S. market compared to one a year ago.

  • Amarin's gross margin on net product revenue was 46%, compared with 79% a year ago. The adjusted gross margin was 72%.

  • Amarin posted an adjusted EPS loss of $(0.09), a shift from a profit of $0.03 a year ago and missing the consensus loss of $(0.06).

  • Price Action: AMRN shares are down 1.57% at $1.30 during the market session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.